WallStreetZenWallStreetZen

NASDAQ: MLYS
Mineralys Therapeutics Inc Stock Ownership - Who owns Mineralys Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Mineralys Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
David Malcom RodmanChief Medical Officer2026-03-17417$15.44
$6.44kBuy
David Malcom RodmanChief Medical Officer2026-03-17417$25.65
$10.70kSell
David Malcom RodmanChief Medical Officer2026-03-133,542$10.20
$36.13kBuy
David Malcom RodmanChief Medical Officer2026-03-13253$27.82
$7.04kSell
David Malcom RodmanChief Medical Officer2026-03-133,079$27.37
$84.26kSell
David Malcom RodmanChief Medical Officer2026-03-1310,726$25.91
$277.92kSell
David Malcom RodmanChief Medical Officer2026-03-134,167$14.25
$59.38kBuy
David Malcom RodmanChief Medical Officer2026-03-126,348$1.08
$6.86kBuy
David Malcom RodmanChief Medical Officer2026-03-126,348$27.37
$173.74kSell
David Malcom RodmanChief Medical Officer2026-03-092,171$16.00
$34.74kBuy

1 of 12

MLYS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when MLYS insiders and whales buy or sell their stock.

MLYS Shareholders

What type of owners hold Mineralys Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Srinivas Akkaraju14.73%12,140,369$286.63MInsider
Samsara Biocapital GP LLC13.05%10,749,832$253.80MInsider
Brian Taylor Slingsby9.60%7,910,038$186.76MInsider
Catalys Pacific LLC9.59%7,903,838$186.61MInstitution
Ra Capital Management LP8.89%7,323,750$172.91MInstitution
Ra Capital Management LP8.89%7,323,750$172.91MInsider
Samsara Biocapital LLC7.13%5,871,018$138.61MInstitution
Fmr LLC6.14%5,057,509$119.41MInstitution
Blackrock Inc5.25%4,327,678$102.18MInstitution
Vanguard Group Inc4.07%3,352,880$79.16MInstitution

1 of 3

MLYS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
MLYS67.62%32.38%Net BuyingNet Selling
TYRA62.54%37.46%Net BuyingNet Selling
STOK52.83%47.17%Net SellingNet Selling
KOD73.04%26.96%Net BuyingNet Buying
NKTR41.27%58.73%Net SellingNet Selling
View Top Biotech Stocks

Mineralys Therapeutics Stock Ownership FAQ

Who owns Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ: MLYS) is owned by 107.23% institutional shareholders, 51.35% Mineralys Therapeutics insiders, and 0.00% retail investors. Srinivas Akkaraju is the largest individual Mineralys Therapeutics shareholder, owning 12.14M shares representing 14.73% of the company. Srinivas Akkaraju's Mineralys Therapeutics shares are currently valued at $287.48M.

If you're new to stock investing, here's how to buy Mineralys Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.